Journal Mobile Options
Table of Contents
Vol. 10, No. 4, 2007
Issue release date: September 2007

Association of Ultrasound Findings with Decision to Continue Down Syndrome Pregnancies

Perry S. · Woodall A.L. · Pressman E.K.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Objective: To evaluate the association of ultrasound findings and other factors with the decision to terminate trisomy-21-affected pregnancies. Methods: We performed a retrospective analysis of trisomy-21-affected pregnancies diagnosed prior to 24 weeks’ gestation. Data were collected on maternal age, indications for prenatal diagnosis, gestational age at diagnosis, marital status, race, parity and ultrasound findings. Logistic regression, χ2, t test and Fishers exact test were used for statistical analysis. Results: Fifty-nine pregnancies were identified with a termination rate of 72.9%. Termination rates were significantly lower in patients with major (50%) or minor (64%) ultrasound abnormalities than in patients with normal ultrasound exams (92%), p = 0.026 and 0.022, respectively. Patients who chose terminations were older (36.1 vs. 32.3), but this did not reach statistical significance (p = 0.059). Conclusion: Patients with abnormal ultrasound results were more likely to continue a trisomy 21 pregnancy.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Robinson A, Linden MG: Down’s syndrome; in Robinson A, Linden MG (eds): Clinical Genetics Handbook, ed 2. Boston, Blackwell, 1993, pp 100–108.
  2. Egan JF: The genetic sonogram in second trimester Down syndrome screening. Clin Obstet Gynecol 2003;46:897–908.
  3. Mansfield C, Hopfer S, Marteau TM: Termination rates after prenatal diagnosis of Down syndrome, spina bifida, anencephaly, and Turner and Klinefelter syndromes: a systematic literature review. Prenat Diagn 1999;19:808–812.
  4. Kramer RL, Jarve RK, Yaron Y, Johnson MP, Lampinen J, Kasperski SB, Evans MI: Determinants of parental decisions after the prenatal diagnosis of Down syndrome. Am J Med Genet 1998;79:172–174.
  5. Forrester M, Merz R: Prenatal diagnosis and elective termination of Down syndrome in a racially mixed population in Hawaii 1987–1996. Prenat Diagn 1999;19:136–141.


Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00